The U.S. FDA's plans to expedite generic-drug approvals should result in more Indian drugs being introduced in the United States, according to an industry official. The application review period is set to change from three years to 11 months. India is the largest foreign supplier of generic medicines to the U.S., with major drugmakers filing 15 to 20 generic-drug applications each year.

Related Summaries